Life-saving bacteria-phobic material coating

Medical innovator Camstent has announced that it has raised a record £850,000, nearly trebling the original £300,000 target, to bring its bacteria-phobic polymer coatings to market.

Currently one in 20 inpatients suffer from a Hospital Acquired Infection (HAI), leading to the loss of thousands of lives globally and adding to costs for healthcare providers. Government research found that even a 10% reduction in infections could save the NHS £100m per annum.

Camstent’s patented bacteria-phobic polymer coatings help better protect against HAIs, changing the physical properties of surfaces to make them inhospitable to bacteria, and dramatically lowering infection rates. Laboratory studies are claimed to show that Camstent coated products perform longer and are more effective than market leading alternatives.

“Current antimicrobial coatings for medical devices fail to prevent infection, but our innovative patented polymer coating has been proven in the lab to resist bacteria colonisation and inhibit biofilm formation,” said Joe Byrne, chief operating officer, Camstent. “This new funding round will accelerate our growth and enable us to bring our first products successfully to market.”

The funding will be used to bring the Camstent Foley Catheter, its first product, to market. This is designed to help combat Catheter Acquired Urinary Tract Infections (CAUTI), which represent 38% of all HAIs. CE mark approval for the device is expected in Q4 2016.

Tom Austin-Morgan

This material is protected by MA Business copyright
See Terms and Conditions.
One-off usage is permitted but bulk copying is not.
For multiple copies contact the sales team.


Supporting Information
Do you have any comments about this article?

Your comments/feedback may be edited prior to publishing. Not all entries will be published.
Please view our Terms and Conditions before leaving a comment.

© MA Business Ltd (a Mark Allen Group Company) 2022